Karyopharm Earnings Call: Trial Wins, Cash Questions

Karyopharm Therapeutics INC ((KPTI)) has held its Q1 earnings call. Read on for the main highlights of the call.

Karyopharm Therapeutics’ latest earnings call mixed upbeat clinical momentum with sobering financial and competitive realities. Management highlighted compelling Phase III data, a growing commercial opportunity and improving P&L trends, yet also acknowledged declining XPOVIO demand, cash runway constraints and regulatory uncertainty that leave execution risk firmly in focus for investors.

SENTRY Delivers Robust Spleen Responses in Myelofibrosis

Phase III SENTRY results showed selinexor plus ruxolitinib achieving a 50% spleen volume reduction rate (SVR35) at week 24 versus 28% for ruxolitinib alone, with p < 0.0001 supporting statistical strength. Management stressed that meaningful spleen reductions emerged as early as week 12 and were sustained through week 36, suggesting a durable treatment effect.

Intriguing Overall Survival Signal and Disease-Modification Hints

The combination therapy produced an overall survival hazard ratio of 0.43 with a nominal p value of 0.0222, pointing to a potentially material survival advantage. Post‑hoc analyses linked achieving SVR35 with better survival and showed 32% of patients on the combo had at least a 20% reduction in variant allele frequency, raising the prospect of disease modification.

ASCO Spotlight and Publication Plans Bolster Credibility

SENTRY data were selected for a late‑breaking oral presentation at ASCO, giving Karyopharm a prominent scientific stage and peer recognition. The company also outlined plans for a peer‑reviewed manuscript in mid‑2026, which could cement the trial’s profile and support future regulatory and commercial discussions.

Endometrial Cancer: EC042 Fully Enrolled on Strong SIENDO Benchmarks

Karyopharm completed enrollment in the EC042 endometrial cancer study with 257 intent‑to‑treat patients and roughly 220 in the primary analysis set, targeting a top‑line readout in mid‑2026. Management repeatedly referenced prior SIENDO results, where p53 wild‑type patients saw median PFS improvements from 3.7 to 13.7 months and, on longer follow‑up, out to 28.4 months, with a key biomarker subgroup nearing 40 months.

Revenue Growth Fueled by Gross-to-Net Tailwinds

Total revenue rose to $35.1 million from $30.0 million, while U.S. XPOVIO net product revenue jumped to $29.2 million from $21.1 million, an increase of about 38%. The headline improvement benefited heavily from a lower gross‑to‑net rate of 21.8% versus 45.0% a year ago, with management estimating an underlying gross‑to‑net around 26% this quarter.

Operating Metrics Improve as Guidance Is Reaffirmed

Net loss narrowed modestly to $22.4 million from $23.5 million, and the company cited a 20% reduction in loss from operations on an underlying basis. Karyopharm reaffirmed 2026 targets for $130–150 million in total revenue, $115–130 million in U.S. XPOVIO revenue and combined R&D plus SG&A spending of $230–245 million.

Balance Sheet Bolstered, Commercial Infrastructure in Place

The quarter closed with $91.2 million in cash, cash equivalents and restricted cash, including roughly $50 million from a March financing. Management underscored that its sales force, market access and medical affairs footprint—already reaching community practices that generate about 60% of U.S. sales—should support launches in myelofibrosis and endometrial cancer without major pre‑approval spending.

Large Myelofibrosis and Endometrial Market Opportunities

Karyopharm sized the U.S. myelofibrosis market at around 20,000 living patients with about 7,000 newly diagnosed annually and roughly 4,000 addressable in first line, supporting a modeled $1 billion peak revenue opportunity for the selinexor plus ruxolitinib regimen. In endometrial cancer, the firm estimated about 17,000 advanced or recurrent cases each year with roughly half being p53 wild‑type, representing a substantial maintenance population.

Underlying XPOVIO Demand Faces Competitive Headwinds

Despite higher reported sales, management acknowledged that underlying demand for XPOVIO declined versus the prior‑year quarter, pressured by new competitors in the market. The company noted that most of the quarter’s revenue growth stemmed from more favorable gross‑to‑net dynamics rather than organic volume growth, highlighting a softer demand backdrop.

Gross-to-Net Swings Highlight Earnings Volatility

Gross‑to‑net discounts moved sharply from 45.0% in the prior‑year quarter, which was distorted by an atypical product return adjustment, to 21.8% this period. By pointing to an underlying rate of about 26%, management sought to normalize expectations but also implicitly flagged that reported revenue can be sensitive to future gross‑to‑net fluctuations.

Short Cash Runway Amplifies Financing Questions

With $91.2 million in cash and equivalents, Karyopharm expects to fund operations only into late third quarter 2026, even after its recent capital raise. The combination of ongoing net losses and heavy R&D and SG&A spending means the company will likely need additional financing or milestone‑driven inflows to bridge to potential commercial inflection points.

Persistent Losses and Elevated Cash Burn

The quarterly net loss of $22.4 million underscores that the business remains far from breakeven despite improved operating metrics. Full‑year guidance calling for $230–245 million in combined R&D and SG&A spend signals a continued high cash burn rate as the firm advances late‑stage trials and prepares for potential launches.

Safety Signals and Data Detail in Focus for SENTRY

Management reported 23 deaths at the time of the SENTRY top‑line data cutoff, describing them as consistent with expectations but giving limited additional detail. Investors and clinicians may push for more granular attribution and subgroup data in future disclosures, especially as regulators scrutinize the risk‑benefit profile of the combination.

Regulatory Path and Market Access Still Unclear

The company has yet to define a clear FDA timeline for the SENTRY program and did not commit to a specific filing schedule on the call, leaving regulatory timing uncertain. Executives also floated the possibility of pursuing compendia listing as an interim route, but cautioned that a compendia‑only strategy might capture only about half the peak market versus a full label.

Forward-Looking Guidance Centers on 2026 Revenue and Key Readouts

Karyopharm’s outlook rests on delivering $130–150 million in 2026 total revenue and $115–130 million from U.S. XPOVIO while managing R&D and SG&A to $230–245 million, backed by the current Q1 run‑rate and gross‑to‑net assumptions. Strategically, investors are watching for the mid‑2026 EC042 readout, further SENTRY analyses and regulatory progress to de‑risk the path toward the company’s modeled $1 billion myelofibrosis opportunity.

The earnings call painted a picture of a biotech with clinically promising assets and meaningful upside but also notable execution, regulatory and funding risks. For investors, the story now hinges on whether SENTRY and EC042 can translate their strong signals into approvals and commercial traction before the cash clock forces dilutive financing or strategic moves.